Patient Reported Outcomes Analyses from AURORA 1 Clinical Trial: Lupus Impact Tracker and LupusPRO (ACR Convergence 2024) - Sep 25, 2024 - Abstract #1538; Pres time: Nov 17, 2024; 10:30 AM - 12:30 PM; Location: Hall C; In Person; "Background/Purpose: Voclosporin used in addition to Mycophenolate Mofetil and low dose oral steroids in patients with active Lupus Nephritis (LN) was found to be superior to Placebo in Phase 3, global, double blind, randomized control trial (AURORA 1). Significant improvements in PROs (LIT and LupusPRO HRQOL domains) were noted among responders and non-responders in the AURORA 1 trial. Significantly larger magnitude and clinically meaningful reductions in negative impacts of lupus on patients' daily lives were noted on the Lupus Impact Tracker among patients that attained CRR as compared to those that did not. LIT or LupusPRO HRQOL domains capture more proximal impacts of the disease or its treatments in clinical trials."
Clinical • Patient reported outcomes • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Pain
|
|
Meenakshi Jolly1; Matt Truman2; Ronald Flauto3; Kathryn Dao4
|